We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Endoscopic Surgery as Effective as Open Surgery for Nasal Cancer

By HospiMedica International staff writers
Posted on 11 Aug 2009
A new study has shown that endoscopic surgery is as valid a treatment option for treating esthesioneuroblastoma (cancer of the nasal cavity) as traditional open surgery and nonsurgical treatments. More...


Researchers from Boston University School of Medicine (BUSM, MA, USA) and Boston Medical Center (MA, USA) conducted a meta-analysis of 23 studies comprising 361 patients treated for esthesioneuroblastoma between 1992 and 2008. The overall treatment and outcome at final follow-up of each patient was recorded. Patients were pooled according to treatment techniques and compared to one another using a Kaplan-Meier survival curve and the Mann-Whitney U test to examine differences in follow-up times and publication years.

The researchers found that surgery yielded more disease-free outcomes and better survival rates than nonsurgical treatment modalities. Log-rank tests showed a greater published survival rate for endoscopic surgery compared to open surgery, even when stratifying for publication year. There was no significant difference in follow-up time. Additionally, review of Kadish tumor staging for each modality showed larger tumors were more often treated with an open approach, but open and endoscopic survival measures were comparable. The study was published in the July 2009 issue of Laryngoscope.

"Although this meta-analysis suggests that the efficacy of endoscopic and endoscopic-assisted surgery is comparable to open surgery for less invasive tumors, further prospective studies are required to establish more definite conclusions, especially for larger tumors,” said lead author Anand Devaiah, M.D., an assistant professor in the departments of otolaryngology neurological surgery. "It helps validate this revolutionary method of surgery that we perform here at BMC, one of the few centers in the world that can offer patients endoscopic skull base surgery for these and other skull base tumors.”

Esthesioneuroblastoma is a very rare cancer that develops in the upper part of the nasal cavity and is thought to derive from neural tissue associated with the sense of smell. While this tumor generally grows slowly, in some cases it progresses rapidly and aggressively; the faster growing tumors are capable of widespread metastasis. The complex nature of this tumor has led to much debate regarding the optimal treatment modality, with the majority of studies showing that the most effective strategy is a combination of surgery and radiotherapy with or without chemotherapy. However, the evolution of surgical techniques has created another surgical option in the form of endoscopic surgery.

Related Links:
Boston University School of Medicine
Boston Medical Center


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.